ImmuPharma (LON:IMM) Shares Down 5.7% – Time to Sell?

ImmuPharma plc (LON:IMMGet Free Report)’s share price was down 5.7% on Wednesday . The company traded as low as GBX 4.20 ($0.05) and last traded at GBX 4.43 ($0.06). Approximately 3,982,092 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 19,990,912 shares. The stock had previously closed at GBX 4.70 ($0.06).

ImmuPharma Stock Down 5.7 %

The stock has a fifty day moving average of GBX 2.60 and a two-hundred day moving average of GBX 1.99. The stock has a market cap of £18.45 million, a price-to-earnings ratio of -443.00 and a beta of 1.53.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzorâ„¢), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Recommended Stories

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.